| Literature DB >> 31968561 |
Mohammad Alfaifi1, Abdulrhman Alsayari2, Narasimman Gurusamy2, Justin Louis2, Serag Eldin Elbehairi1, Kumar Venkatesan2, Sivakumar Annadurai2, Yahya I Asiri2, Ali Shati1, Kamel Saleh1, Helmi Alboushnak1, Heba Handoussa3, Abdullatif Bin Muhsinah2, Amira Abdel Motaal2.
Abstract
Kleinia pendula (Forssk.) DC. is a prostrate or pendent dark green succulent herb found in the southwestern mountain regions of Saudi Arabia. The literature survey of the plant reveals a lack of phytochemical and pharmacological studies, although traditional uses have been noted. The objective of the present work was to assess the in vivo analgesic and anti-inflammatory activities, as well as, the in vitro cytotoxic potential of the fractions of Kleinia pendula, and correlate these activities to the plant metabolites. The methanolic extract of Kleinia pendula was subjected to fractionation with n-hexane, ethyl acetate, chloroform, n-butanol, and water. The fractions were screened for their analgesic and anti-inflammatory activities, as well as cytotoxic activity against breast, liver, and colon cancer cell lines. The n-hexane and chloroform fractions of Kleinia pendula showed significant cytotoxic activity against all three cancer cell lines tested. The ethyl acetate and chloroform fractions showed significant analgesic and anti-inflammatory activities. The metabolites in these three active fractions were determined using UPLC-PDA-ESI-MS. Thus, the analgesic and anti-inflammatory activities of the plant were attributed to its phenolic acids (caffeoylquinic acid derivatives, protocatechuic, and chlorogenic acids). While fatty acids and triterpenoids such as (tormentic acid) in the hexane fraction are responsible for the cytotoxic activity; thus, these fractions of Kleinia pendula may be a novel source for the development of new plant-based analgesic, anti-inflammatory, and anticancer drugs.Entities:
Keywords: Kleinia pendula (Forssk.) DC.; analgesic; anti-inflammatory; cytotoxic; fraction; metabolite
Year: 2020 PMID: 31968561 PMCID: PMC7024144 DOI: 10.3390/molecules25020418
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Kleinia pendula.
Figure 2Analgesic activity of various fractions of Kleinia pendula at different doses and time points. The (CHCl3) fraction at doses of 100, 200, and 300 mg/kg body weight of the animal (A) exhibited analgesic activity. Ethyl acetate (EA) fraction at doses of 100, 200, and 300 mg/kg body weight of the animal (B) exhibited analgesic activity. The hexane fraction at doses of 100, 200, and 300 mg/kg body weight of the animal (C) exhibited low analgesic activity. Diclofenac sodium (10 mg/kg) was used as a positive control, and standard saline was used as negative control. The values are represented as mean ± SEM. Statistical analysis was done using one-way analysis of variance using the Dunnett’s posthoc test.
Figure 3Anti-inflammatory activity of various fractions of Kleinia pendula. (A) Anti-inflammatory activity of various fractions of Kleinia pendula at different doses and time points. Chloroform (CHCl3) fraction at doses of 100, 200 and 300 mg/Kg body weight of the animal exhibited anti-inflammatory activity. (B) Ethyl acetate (EA) fraction at doses of 100, 200 and 300 mg/kg body weight of the animal exhibited anti-inflammatory activity. Diclofenac sodium (10 mg/kg) was used as a positive control, and standard saline was used as negative control. The values are represented as Mean ± SEM. Statistical analysis was done using one-way analysis of variance using Dunnett’s posthoc test.
Cytotoxic activities of extract/fractions of Kleinia pendula against different cancer cell lines.
| Fractions/Extract | IC50 (μg/mL) | ||
|---|---|---|---|
| MCF-7 (µg) | HepG2 (µg) | HCT-116 (µg) | |
| Methanol extract | 3.2 ± 0.6 | 3.17 ± 0.69 | 4.8 ± 0.6 |
| Hexane fraction | 0.07 ± 0.03 | 0.19 ± 0.02 | 0.11 ± 0.01 |
| Chloroform fraction | 0.13 ± 0.07 | 0.24 ± 0.03 | 0.19 ± 0.15 |
| Ethyl acetate fraction | 90.22 ± 18.6 | ≥100 | 28.1 ± 5.3 |
| Butanol fraction | ≥100 | ≥100 | ≥100 |
| Water fraction | ≥100 | ≥100 | ≥100 |
| Doxorubicin | 0.014 ± 0.008 | 0.0065 ± 0.005 | 0.013 ± 0.0005 |
p values less than 0.05 are considered statistically significant. IC50 values of the fractions were significantly higher than that of positive control (Doxorubicin).
Peak assignment using UPLC-PDA-ESI-MS of metabolites detected in ethyl acetate fraction (negative mode).
| Peak | Retention Time | Identified Compd. | UV-Vis (λ Max) | [M − H]− | Fragment Ions ( | Percentage (%) | Ref. |
|---|---|---|---|---|---|---|---|
|
| 4.2 | Quinic acid | 323 | 191 | 178, 173, 148, 110 | 0.8 | [ |
|
| 6.2 | Protocatechuic acid | 320 | 153 | 113, 105 | 0.5 | [ |
|
| 20.48 | Di-caffeoyl quinic acid | 246, 310 | 515 | 191 | 5.7 | [ |
|
| 21.32 | Chlorogenic acid | 246, 310 | 353 | 191 | 1.21 | [ |
|
| 21.98 | Feruloyl-quinic acid | 247,310 | 367 | 191 | 0.62 | [ |
|
| 22.9 | Isorhamnetin-3- | 230, 262 | 623 | 315, 153 | 3.2 | [ |
|
| 23.09 | Feruloyl-quinic acid | 247,310 | 367 | 191 | 1.32 | [ |
|
| 24.6 | Trihydroxyphenethyl- | 232, 282 | 621 | 487, 469 | 3.4 | [ |
|
| 25.72 | Sinapic acid hexoside | 310 | 385 | 223 | 4.82 | [ |
|
| 25.85 | Di-caffeoyl-hexuronide derivative | 328 | 710 | 355, 135, 113 | 2.5 | [ |
|
| 26.27 | Chlorogenic acid | 246, 310 | 353 | 191 | 4.95 | [ |
|
| 28.86 | Feruloyl-quinic acid | 333 | 367 | 191 | 5.1 | [ |
|
| 29.22 | Sulphate conjugate of dimethyl gallic acid | 260 | 277 | 197,163 | 1.6 | [ |
|
| 30.62 | Di-methylgallic acid derivative | 267 | 291 | 155 | 0.7 | [ |
|
| 35.9 | Coumaroyl-shikimic acid | 225 | 319 | 155 | 0.92 | [ |
|
| 38.9 | Apigenin-6,8-di-C-glucoside | 246, 310 | 593 | 297,135 | 1.6 | [ |
|
| 40.21 | Formylipolamiidic acid | Undetected | 419 | 401, 257, 155 | 0.9 | [ |
|
| 42.82 | Procyanidin B3 | 330 | 579 | 453, 127 | 0.5 | [ |
Peak assignment using UPLC-PDA-ESI-MS of metabolites detected in the chloroform fraction (negative mode).
| Peak | Retention Time | Identified Compd. | UV-Vis (λ Max) | [M − H]− | Fragment Ions ( | Percentage (%) | Ref. |
|---|---|---|---|---|---|---|---|
|
| 3.5 | Hexahydroxydiphenoyl (HHDP)-galloylglucose | 274 | 633 | 301, 257, 229 | 5.4 | [ |
|
| 5.18 | Dihydroxy-4-methoxyl isoflavan | 226, 284 | 271 | 227, 135 | 3.75 | [ |
|
| 5.2 | Gallocatechin | 274 | 305 | 179 | 1.29 | [ |
|
| 6.2 | HHDP-galloylglucose | 274 | 633 | 301, 257, 229 | 1.3 | [ |
|
| 6.9 | Trihydroxyphenethyl- | 232, 282 | 621 | 487, 469 | 3.4 | [ |
|
| 7.38 | unidentified | 230, 290 | 604 | 582, 462, 342 | 2.38 | [ |
|
| 9.2 | Methylretusin | 230, 283 | 297 | 281, 239 | 0.18 | [ |
|
| 9.35 | Acyl-feruloyl-4- | 220, 232 | 571 | 277, 191 | 0.95 | [ |
|
| 12.08 | Glycycoumarin hydroxylate glucuronide | 258 | 559 | 338 | 3.29 | [ |
|
| 12.65 | Sulfate conjugate of glycycoumarin | 283 | 447 | 367 | 2.01 | [ |
|
| 14.78 | trisgalloyl (hexahydroxydiphenoyl) glucose derivative | 275 | 907 | 765,191 | 0.72 | [ |
Peak assignment using UPLC-PDA-ESI-MS of metabolites detected in hexane fraction (negative mode).
| Peak | Retention Time | Identified Compd. | [M − H]− ( | Fragment Ions ( | Percentage (%) | Ref. |
|---|---|---|---|---|---|---|
|
| 4.2 | Tinosposinenside B | 581 | 379, 343, 297 | 0.21 | [ |
|
| 4.93 | Amritoside A | 555 | 537, 513 | 0.42 | [ |
|
| 4.95 | Isocryptotanshinone II | 297 | 225, 211 | 0.8 | [ |
|
| 5.23 | Linolenic acid | 277 | 250, 219 | 3.5 | [ |
|
| 11.3 | Octadecadienoic acid derivative | 265 | 249, 179 | 0.2 | [ |
|
| 14.2 | Tanshinone IIB | 311 | 275, 250 | 0.73 | [ |
|
| 25.6 | Salvianolic acid G | 339 | 277, 249 | 0.35 | [ |
|
| 27.97 | Tinocrisposide | 535 | 521, 355 | 1.9 | [ |
|
| 31.43 | Tormentic acid | 487 | 469 | 4.9 | [ |
|
| 34.3 | 6,7-Dehydroroyleanone | 315 | 297, 216 | 1.87 | [ |
|
| 36.8 | Salvianolic acid D | 417 | 197, 175, 135 | 1.2 | [ |
|
| 37.80 | Dehydrated derivative of Tinosposinenside B | 419 | 297 | 3.75 | [ |
|
| 38.45 | 5-Hydroxydavisiosidec | 513 | 197 | 4.89 | [ |
|
| 39.5 | Citrostadienyl | 432 | 419 | 4.3 | [ |
|
| 40.58 | Unidentified | 319 | 305, 291, 277 | 6.75 | n.d. |
Figure 4UPLC-PDA-ESI-MS in the bioactive ethyl acetate fractions.
Figure 5UPLC-PDA-ESI-MS in the chloroform fractions.
Figure 6UPLC-PDA-ESI-MS in n-hexane fractions.